Use of <scp>sodium–glucose</scp> co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry

Aims Use of sodium–glucose co-transporter 2 inhibitors (SGLT2i) in real-world heart failure (HF) is poorly characterised. In contemporary patients with HF and type diabetes mellitus (T2DM) we assessed over time SGLT2i use, clinical characteristics outcomes associated use. Methods results Type enrolled the Swedish Registry between 2016–2018 were considered. We performed multivariable logistic regression models to assess independent predictors use Cox a 1:3 propensity score-matched cohort relevant subgroups investigate association outcomes. Of 6805 eligible T2DM, 376 (5.5%) received SGLT2i, whose increased 12% on treatment at end 2018. Independent younger age, specialty care, ischaemic disease, preserved kidney function, absence anaemia. Over median follow-up 256 days, was 30% lower risk cardiovascular (CV) death/first hospitalisation (hazard ratio 0.70, 95% confidence interval 0.52–0.95), which consistent regardless ejection fraction, background metformin function. also all-cause CV death, hospitalisation, death/myocardial infarction/stroke. Conclusion time, more common specialist renal mortality morbidity.